Product Overview
[Drug Name]
Generic Name: Silybin Meglumine Tablets
Trade Name: Xilibinan Silybin Meglumine Tablets 50mg*48 Tablets
Pinyin Full Code: XiLiBinAn ShuiFeiJiBinPuJiaAnPian 50mg*48 Tablets
[Main Ingredient]
Silybin Meglumine
[Indications/Main Functions]
For the adjunctive treatment of acute and chronic hepatitis, early cirrhosis, and toxic liver damage.
[Specifications]
50mg*48 tablets
[Dosage and Administration]
Oral administration. Take 100-200mg (2-4 tablets) three times daily, or as directed by a physician.
[Adverse Reactions]
Occasionally, dizziness and upper abdominal discomfort may occur.
[Drug Interactions]
Drug interactions may occur if used with other medications. Please consult your physician or pharmacist for details.
[Pharmacology and Toxicology]
1. Pharmacology:
Animal experiments show that this product can increase the microsomal enzyme activity of hepatocytes and accelerate the liver's detoxification ability; it can also reduce the increase in rat serum glutamic-alanine aminotransferase caused by carbon tetrachloride; it can also stabilize cell membranes of various types of liver damage caused by liver poisons such as carbon tetrachloride, phalloidin, thioacetamide, and crotalin, thereby achieving a significant liver protection effect.
2. Toxicology:
(1) The LD50 value of the acute toxicity test in mice could not be measured after oral administration.
(2) Subacute toxicity test in dogs: After oral administration, no significant changes were observed in the heart, lungs, liver, kidneys, pancreas, spleen, intestines, adrenal glands, etc.
